Clinical Trial Detail

NCT ID NCT01838395
Title Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors BioLineRx, Ltd.
Indications

acute myeloid leukemia

Therapies

BKT140 + Cytarabine

Age Groups: adult

No variant requirements are available.